Navigation Links
Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on Tuesday, August 19th at 1:30 p.m. PDT
Date:8/19/2008

ntains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska will present at the fourth annual Noble Financial Equity Conference on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Las Vegas, Nevada. Duska's presentation is scheduled for 1:30 p.m. PDT. Dr. Kuo will also be available for one-on-one meetings throughout the day. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as requi
'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
2. Duska Therapeutics Obtains Standard & Poors Listing
3. Arno Therapeutics Announces Second Quarter 2008 Financial Results
4. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
5. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
6. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Research and Markets ... "Global DNA Diagnostics Market (Product types, Application, Technology, ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... report to their offering. This ... techniques, end users and Geography) Global Size, Industry ...
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... The organizers of Pharma,ChemOutsourcing Conference & Exhibition ... and biotech company speakers who,will gather in ... around the,exploding chemical outsourcing activities reshaping R ... industry, reports Apaporis LLC. The,conference program may ...
... 2 ev3 Inc. (Nasdaq:,EVVV), a global endovascular device ... of 2008 and its revised financial,guidance for 2008., ... in the,first quarter of 2008 representing a 65% increase ... 10% increase over the fourth quarter of 2007. The,increase ...
... The timing of the live teleconference should have read: "9:00 am ... follows: Resverlogix Notice ... ... pleased to announce that it will host a live,teleconference on May 8, 2008 at ...
Cached Biology Technology:Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 3ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 4ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 5ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 6ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 7ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 8ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 9ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 10ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 11ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 12/C O R R E C T I O N from Source -- Resverlogix Corp./ 2
(Date:10/22/2014)... Calif. , Oct. 20, 2014 The ... United States Air Force Research Laboratory (AFRL), has chosen ... Medicine (AzCIM) at the University of Arizona College of ... research funding.  The AzCIM project,s goal is to assess ... to collect different volumes of sweat under a variety ...
(Date:10/22/2014)... Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... services, today reported financial results for its third quarter ended ... of 2014 was $6.0 million, an increase of 40% compared ... income in the third quarter of 2014 was $4.1 million ... Higher operating income in the current three month period was ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2
... Ill. (March 28, 2011)Deep vein thrombosis, or DVT: it,s ... long plane ride. The Society of Interventional Radiology wants ... serious condition, which can lead to post-thrombotic syndrome, pulmonary ... "Individuals and their doctors need to be ...
... of Utah scientists used invisible infrared light to make ... signals to the brain. The discovery someday might improve ... restore vision, maintain balance and treat movement disorders like ... with optical infrared pulses instead of electrical pulses," which ...
... Researchers have described how the most common gene ... of cancer development and how it can cooperate with ... leukaemia. The researchers suggest that three critical steps ... ones, each subverting a different cellular process. By charting ...
Cached Biology News:Interventional radiologists take lead on reducing disability from dangerous blood clots 2Interventional radiologists take lead on reducing disability from dangerous blood clots 3Interventional radiologists take lead on reducing disability from dangerous blood clots 4Will we hear the light? 2Will we hear the light? 3Will we hear the light? 4Will we hear the light? 5The gene processes that drive acute myeloid leukaemia 2The gene processes that drive acute myeloid leukaemia 3
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Mycoplasma tested...
Biology Products: